No­var­tis turns to Ox­ford Bio­Med­ica for a ma­jor CAR-T sup­ply deal

Ox­ford Bio­Med­ica has scored a ma­jor sup­ply con­tract with No­var­tis for the lentivi­ral vec­tors the phar­ma gi­ant us­es in its CAR-T drugs, in­clud­ing the in­dus­try-lead­ing CTL019, now un­der FDA re­view.

Ox­ford Bio­Med­ica is get­ting a $10 mil­lion pay­day to get the al­liance start­ed, and says it can earn up to $100 mil­lion over the course of the three-year pact. No­var­tis has an op­tion to bump that to 5 years.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.